Assessing the Mechanisms and Impact of a Novel Cannabinoid Product for Gynecologic Pain

Inclusion Criteria: * Provides informed consent * Sex assigned female at birth * Capable of having menstrual cycles * Aged 21+ * Endorses one of the following gynecologic pain conditions: endometriosis, adenomyosis, chronic pelvic inflammatory disease (PID) * Stable medication/psychotherapy regimens for at least 3 months prior to starting the study, including hormonal contraceptives Additional inclusion criteria for those in the PK subgroup: * Willingness to participate in the PK procedures (i.e., agree to an indwelling catheter with repeated blood collection) Exclusion Criteria: * Meets criteria for DSM-5 classification of current substance use disorder, psychotic disorder, bipolar disorder, or an eating disorder * Currently uses cannabinoid products * Positive urine pregnancy test, are trying to become pregnant, or are currently breastfeeding * Presence of a serious or unstable medical illness, including liver/kidney disease, cardiovascular disease, neurological disorder, and conditions or medications that impact drug absorption or gastric emptying (e.g., GLP-1 agonists) * Comorbid neuropathic pain or cancer-related pain * Disclosure of a genetic polymorphism affecting CYP2C9 function * Liver function test (LFT) values \>3x the upper limit of normal (ULN) at the baseline visit